Lotus Pharmaceuticals, Inc. Announces Certain Clarification to its Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report for the Quarter ended June 30, 2009
|
| Posted
:
Thu, 05 Nov 2009 13:02:06 GMT |
| Author
:
Lotus Pharmaceuticals, Inc. |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
BEIJING, Nov. 5 LTUS-Clarify-10-K
BEIJING, Nov. 5 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.
(OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and
producer of prescriptions drugs and licensed national seller of pharmaceutical
products in the People's Republic of China, today announced correction to be
made on its annual and quarterly filings with the SEC.
Lotus Pharmaceuticals, Inc., and its US subsidiary, together with its
wholly-owned foreign enterprise registered in Beijing ("Lotus Holding") have a
set of contractual agreements with two operating entities in China ("Lotus
East"). The company's structure is commonly used to allow foreign investors to
invest operating businesses in China and allows financial reporting of
consolidated financial statements. Lotus Holding is a holding company without
material operation; Lotus East is one of the Company's operating entities. The
key management of Lotus Holding is the same as Lotus East. Historically, and
agreed by the Board of Directors of Lotus, income generated by Lotus East has
been retained in China to fuel, in part, internal growth, and fund certain
expenses of Lotus Holding. To date, Lotus has neither experienced liquidity
problem nor does it currently foresee liquidity problems.
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of
prescription drugs and a licensed national seller of pharmaceutical items in
the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd.
and En Ze Jia Shi Pharmaceutical, Ltd. Lotus's current drug development
pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma,
and diabetes. More than 8,000 products are sold by Liang Fang directly and
indirectly through its national sales channels to hospitals, clinics and drugs
stores in 30 provinces.
Safe Harbor Statement
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may," or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
could cause the actual results of the Company to differ materially from the
results expressed or implied by such statements, including, but not limited to,
changes from anticipated levels of sales, future national or regional economic
and competitive and regulatory conditions, changes in relationships with
customers, access to capital, increased costs, difficulties in developing and
marketing new products, marketing existing products, customer acceptance of
existing and new products, the time to get new drugs approved by the SFDA and
other factors. Additional information regarding risks can be found in the
Company's Annual Report on Form 10K and its older filings with the SEC.
Accordingly, although the Company believes that the expectations reflected in
such forward-looking statements are reasonable, there can be no assurance that
such expectations will prove to be correct. The Company has no obligation to
update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.com
SOURCE Lotus Pharmaceuticals, Inc.
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Research and Markets: Global Mobile Operator Forecast Report for 2009 - 2013 DUBLIN -
Research and Markets (
Research and Markets: The Global Animation Industry - There is Perhaps no Genre of Film or Television More Global Than Animation DUBLIN -
Research and Markets (
Representatives of the nomination committee of Saab AB for the Annual General Meeting 2010 STOCKHOLM -
Regulatory News:
There has been a change in the nomination committee of Saab AB
(STO:SAABB). After the change the nomination committee consists of the
following representatives.
Representatives:Marcus Wallenberg, Chairman of Saab AB
Handyman Services in Colorado Springs Raising the Bar on Customer Satisfaction (EMAILWIRE.COM, November 26, 2009 ) Colorado Springs, CO – Handyman Services are popping up all over the place. More and more people are going into business for themselves due to the job market and unemployment rates. Handyman service is an easy b..
Handyman Services in Colorado Springs are Honest and Dependable (EMAILWIRE.COM, November 26, 2009 ) Colorado Springs, CO – Handyman Services are advertised everywhere; Google search handyman services in your area and you will find many who claim to be the best and cheapest around. Unfortunately, handyman servic..
Track Contributions Made to Political Candidates at IQElections.com (EMAILWIRE.COM, November 26, 2009 ) New York, NY - IQ Elections now offers a Directory of Political Candidates for interested voters who want to research campaign contributions made to politicians nationwide. This directory includes all candidates wh..
CHRYSLER Bankruptcy News, Issue No. 32 (EMAILWIRE.COM, November 26, 2009 ) FAIRLESS HILLS, Pa. -- Bankruptcy Creditors' Service, Inc., published Issue No. 32 of CHRYSLER BANKRUPTCY NEWS today. The 48-page newsletter contains stories with these headlines:[00917] CHRYSLER GROUP MAY LOSE OV..
|
|
|
|
|
|
|
|
|